Could a Pre-Surgery pill slow head and neck cancer?
NCT ID NCT03138070
First seen Feb 01, 2026 · Last updated Jun 22, 2026 · Updated 16 times
Summary
This study tested whether taking the drug BYL719 for 14 days before surgery changes certain proteins in head and neck cancer tumors. Fifteen patients with resectable head and neck cancer took the pill daily until their planned surgery. Researchers compared tumor samples taken before and after treatment to see if the drug affected cancer-related markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
London Health Sciences Centre, London Regional Cancer Program
London, Ontario, N6A 4L6, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BYL719 (Alpelisib)
What this could lead to
If successful, this could point toward a new treatment option for head and neck cancer by showing that BYL719 affects tumor biology.
What could go wrong
This is a very small, early-phase study with only 15 people, designed mainly to measure biological changes, not to prove the drug works as a treatment. Results may not lead to a new therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.